$AMRX
Amneal Pharmaceuticals, Inc.

2022 Q1 Form 10-Q Financial Statement

#000172312822000016 Filed on May 06, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $497.6M $493.1M
YoY Change 0.92% -1.09%
Cost Of Revenue $323.1M $301.5M
YoY Change 7.14% -3.84%
Gross Profit $174.6M $191.6M
YoY Change -8.87% 4.39%
Gross Profit Margin 35.08% 38.85%
Selling, General & Admin $98.67M $90.73M
YoY Change 8.75% 16.35%
% of Gross Profit 56.52% 47.36%
Research & Development $52.80M $48.18M
YoY Change 9.58% 32.44%
% of Gross Profit 30.24% 25.15%
Depreciation & Amortization $57.82M $55.50M
YoY Change 4.17% -4.48%
% of Gross Profit 33.12% 28.97%
Operating Expenses $151.5M $138.9M
YoY Change 9.04% 21.47%
Operating Profit $23.31M $45.91M
YoY Change -49.23% -20.56%
Interest Expense -$33.34M -$33.89M
YoY Change -1.62% -15.07%
% of Operating Profit -143.04% -73.81%
Other Income/Expense, Net -$33.23M -$31.00M
YoY Change 7.17% -30.25%
Pretax Income -$9.921M $14.90M
YoY Change -166.57% 11.69%
Income Tax -$3.500M $400.0K
% Of Pretax Income 2.68%
Net Earnings -$8.817M $12.75M
YoY Change -169.16% -89.41%
Net Earnings / Revenue -1.77% 2.59%
Basic Earnings Per Share -$0.01 $0.05
Diluted Earnings Per Share -$0.01 $0.04
COMMON SHARES
Basic Shares Outstanding 149.9M shares 148.0M shares
Diluted Shares Outstanding 149.9M shares 151.2M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $210.5M $452.1M
YoY Change -53.44% 11.57%
Cash & Equivalents $210.5M $452.1M
Short-Term Investments
Other Short-Term Assets $56.86M $78.80M
YoY Change -27.84% 92.67%
Inventory $512.2M $497.0M
Prepaid Expenses
Receivables $538.3M $530.6M
Other Receivables $47.21M $1.100M
Total Short-Term Assets $1.390B $1.560B
YoY Change -10.9% -12.07%
LONG-TERM ASSETS
Property, Plant & Equipment $500.9M $471.2M
YoY Change 6.31% 0.77%
Goodwill $602.9M $522.8M
YoY Change 15.33% 1.56%
Intangibles $1.210B $1.263B
YoY Change -4.21% -14.39%
Long-Term Investments
YoY Change
Other Assets $63.94M $19.56M
YoY Change 226.89% -26.06%
Total Long-Term Assets $2.499B $2.400B
YoY Change 4.12% -8.28%
TOTAL ASSETS
Total Short-Term Assets $1.390B $1.560B
Total Long-Term Assets $2.499B $2.400B
Total Assets $3.889B $3.960B
YoY Change -1.8% -9.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $539.7M $574.3M
YoY Change -6.02% -5.37%
Accrued Expenses $12.59M $9.500M
YoY Change 32.56% -41.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $30.52M $29.82M
YoY Change 2.37% 0.27%
Total Short-Term Liabilities $602.0M $636.8M
YoY Change -5.45% -34.02%
LONG-TERM LIABILITIES
Long-Term Debt $2.673B $2.728B
YoY Change -2.04% -1.58%
Other Long-Term Liabilities $32.87M $63.79M
YoY Change -48.48% -21.1%
Total Long-Term Liabilities $2.863B $2.944B
YoY Change -2.73% -2.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $602.0M $636.8M
Total Long-Term Liabilities $2.863B $2.944B
Total Liabilities $3.465B $3.580B
YoY Change -3.22% -9.92%
SHAREHOLDERS EQUITY
Retained Earnings -$278.4M -$280.1M
YoY Change -0.63% 6.58%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $391.1M $323.0M
YoY Change
Total Liabilities & Shareholders Equity $3.889B $3.960B
YoY Change -1.8% -9.81%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$8.817M $12.75M
YoY Change -169.16% -89.41%
Depreciation, Depletion And Amortization $57.82M $55.50M
YoY Change 4.17% -4.48%
Cash From Operating Activities $120.3M $148.1M
YoY Change -18.76% 202.14%
INVESTING ACTIVITIES
Capital Expenditures $10.79M $11.78M
YoY Change -8.35% 59.85%
Acquisitions $0.00
YoY Change -100.0%
Other Investing Activities -$84.71M $0.00
YoY Change -100.0%
Cash From Investing Activities -$97.40M -$12.69M
YoY Change 667.31% -95.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$61.57M -$26.15M
YoY Change 135.46% -105.59%
NET CHANGE
Cash From Operating Activities $120.3M $148.1M
Cash From Investing Activities -$97.40M -$12.69M
Cash From Financing Activities -$61.57M -$26.15M
Net Change In Cash -$40.19M $108.7M
YoY Change -136.98% -57.22%
FREE CASH FLOW
Cash From Operating Activities $120.3M $148.1M
Capital Expenditures $10.79M $11.78M
Free Cash Flow $109.6M $136.4M
YoY Change -19.66% 227.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001723128
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38485
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Amneal Pharmaceuticals, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0546926
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
400 Crossing Boulevard,
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bridgewater
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08807
CY2022Q1 dei City Area Code
CityAreaCode
908
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
947-3120
CY2022Q1 dei Security12b Title
Security12bTitle
Class A Common Stock, par value $0.01 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
AMRX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
497633000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493105000 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
323062000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
301543000 USD
CY2022Q1 us-gaap Gross Profit
GrossProfit
174571000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
191562000 USD
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
98665000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90726000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52798000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48182000 USD
CY2022Q1 us-gaap Royalty Expense
RoyaltyExpense
764000 USD
CY2021Q1 us-gaap Royalty Expense
RoyaltyExpense
3582000 USD
CY2022Q1 amrx Business Combination Acquisition Related Costs Transaction Related And Integration Expense
BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense
434000 USD
CY2021Q1 amrx Business Combination Acquisition Related Costs Transaction Related And Integration Expense
BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense
2802000 USD
CY2022Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
2326000 USD
CY2021Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
731000 USD
CY2021Q1 us-gaap Restructuring Charges
RestructuringCharges
363000 USD
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
200000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
23305000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
45907000 USD
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-33335000 USD
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-33885000 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2013000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2088000 USD
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2122000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
794000 USD
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33226000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31003000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9921000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14904000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3461000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
359000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-6460000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
14545000 USD
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4742000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7839000 USD
CY2022Q1 amrx Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest
NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest
-1718000 USD
CY2021Q1 amrx Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest
NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest
6706000 USD
CY2022Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
438000 USD
CY2021Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2156000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6706000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
149892000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148013000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149892000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151220000 shares
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-6460000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
14545000 USD
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4742000 USD
CY2021Q1 amrx Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest
NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest
6706000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6706000 USD
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4079000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7839000 USD
CY2022Q1 amrx Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest
NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest
-1718000 USD
CY2022Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
438000 USD
CY2021Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2156000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-6366000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
53624000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
20772000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
24955000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
7302000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
24590000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
7104000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
22434000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
13810000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
210477000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
247790000 USD
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6068000 USD
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
8949000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
416600000 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
538309000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
662583000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
512241000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
489389000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
121408000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
110218000 USD
CY2022Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1175000 USD
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1179000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
1389678000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1520108000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
500911000 USD
CY2022Q1 amrx Percentage Of Tax Benefits Under Tax Receivable Agreement
PercentageOfTaxBenefitsUnderTaxReceivableAgreement
0.85
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
514158000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
602893000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
593017000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1209818000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1166922000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
63943000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20614000 USD
CY2022Q1 us-gaap Assets
Assets
3888968000 USD
CY2021Q4 us-gaap Assets
Assets
3939664000 USD
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
539734000 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
583345000 USD
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
30523000 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
30614000 USD
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
15960000 USD
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
47861000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
602043000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
677243000 USD
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2672661000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2680053000 USD
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.024
CY2022Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
38443000 USD
CY2021Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
38038000 USD
CY2022Q1 us-gaap Due To Affiliate Noncurrent
DueToAffiliateNoncurrent
10371000 USD
CY2021Q4 us-gaap Due To Affiliate Noncurrent
DueToAffiliateNoncurrent
9619000 USD
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32866000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
38903000 USD
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2863098000 USD
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2878541000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2022Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
16420000 USD
CY2021Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
16907000 USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000 USD
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
666799000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
658350000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278353000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-276197000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-349000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-24827000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
391125000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
360340000 USD
CY2022Q1 us-gaap Minority Interest
MinorityInterest
16282000 USD
CY2021Q4 us-gaap Minority Interest
MinorityInterest
6633000 USD
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
407407000 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
366973000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3888968000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3939664000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-6460000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
14545000 USD
CY2022Q1 amrx Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs
DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
57815000 USD
CY2021Q1 amrx Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs
DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
55549000 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-3140000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1970000 USD
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2195000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2183000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8065000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5330000 USD
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
3578000 USD
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
16021000 USD
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
200000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1155000 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1431000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-124268000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-108385000 USD
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
25549000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
20283000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4423000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-602000 USD
CY2022Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-4000 USD
CY2021Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-301000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-48777000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-37226000 USD
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
5132000 USD
CY2021Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
3260000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
120343000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
148128000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10793000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11776000 USD
CY2022Q1 amrx Payments To Acquire Property Plant And Equipment Deposits
PaymentsToAcquirePropertyPlantAndEquipmentDeposits
1888000 USD
CY2021Q1 amrx Payments To Acquire Property Plant And Equipment Deposits
PaymentsToAcquirePropertyPlantAndEquipmentDeposits
917000 USD
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
84714000 USD
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-97395000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12693000 USD
CY2022Q1 amrx Repayments Of Long Term Debt And Financing Lease Obligations
RepaymentsOfLongTermDebtAndFinancingLeaseObligations
9796000 USD
CY2021Q1 amrx Repayments Of Long Term Debt And Financing Lease Obligations
RepaymentsOfLongTermDebtAndFinancingLeaseObligations
23630000 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
111000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
676000 USD
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3001000 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2102000 USD
CY2022Q1 amrx Tax Distribution To Noncontrolling Interest Financing Activities
TaxDistributionToNoncontrollingInterestFinancingActivities
3164000 USD
CY2021Q1 amrx Tax Distribution To Noncontrolling Interest Financing Activities
TaxDistributionToNoncontrollingInterestFinancingActivities
0 USD
CY2022Q1 us-gaap Payments For Repurchase Of Redeemable Noncontrolling Interest
PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
1722000 USD
CY2021Q1 us-gaap Payments For Repurchase Of Redeemable Noncontrolling Interest
PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
0 USD
CY2022Q1 amrx Payment Of Deferred Consideration For Acquisition Related Party
PaymentOfDeferredConsiderationForAcquisitionRelatedParty
43998000 USD
CY2021Q1 amrx Payment Of Deferred Consideration For Acquisition Related Party
PaymentOfDeferredConsiderationForAcquisitionRelatedParty
0 USD
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
93000 USD
CY2022Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
CY2021Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1000000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-61570000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-26149000 USD
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1572000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-593000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-40194000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
108693000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
256739000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
347121000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216545000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
455814000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
210477000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
452097000 USD
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6068000 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
3717000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216545000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
455814000 USD
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
27289000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
29917000 USD
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4387000 USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
733000 USD
CY2022Q1 amrx Tax Distribution To Non Controlling Interest
TaxDistributionToNonControllingInterest
3284000 USD
CY2021Q1 amrx Tax Distribution To Non Controlling Interest
TaxDistributionToNonControllingInterest
9757000 USD
CY2022Q1 amrx Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition
NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisition
8796000 USD
CY2021Q1 amrx Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition
NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisition
0 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
366973000 USD
CY2021Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
16907000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8817000 USD
CY2022Q1 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
2357000 USD
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4079000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8065000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
111000 USD
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-3144000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
53624000 USD
CY2022Q1 amrx Temporary Equity Tax Distribution
TemporaryEquityTaxDistribution
2005000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
883000 USD
CY2022Q1 amrx Temporary Equity Reclassification Of Redeemable Non Controlling Interest
TemporaryEquityReclassificationOfRedeemableNonControllingInterest
883000 USD
CY2022Q1 amrx Temporary Equity Acquisition Of Redeemable Non Controlling Interest
TemporaryEquityAcquisitionOfRedeemableNonControllingInterest
1722000 USD
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
407407000 USD
CY2022Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
16420000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
344932000 USD
CY2020Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
11804000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
12749000 USD
CY2021Q1 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
1796000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-6366000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5330000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
676000 USD
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2149000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
20772000 USD
CY2021Q1 amrx Temporary Equity Tax Distribution
TemporaryEquityTaxDistribution
521000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
366708000 USD
CY2021Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
13079000 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:106%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.</span></div>
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
497633000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493105000 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2156000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6706000 USD
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
149892000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148013000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149892000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151220000 shares
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3500000 USD
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.349
CY2022Q1 amrx Liabilities Under Tax Receivable Agreement Noncurrent
LiabilitiesUnderTaxReceivableAgreementNoncurrent
206300000 USD
CY2021Q4 amrx Liabilities Under Tax Receivable Agreement Noncurrent
LiabilitiesUnderTaxReceivableAgreementNoncurrent
206300000 USD
CY2021Q2 amrx Percentage Of Tax Benefits Under Tax Receivable Agreement
PercentageOfTaxBenefitsUnderTaxReceivableAgreement
0.85
CY2022Q1 amrx Liabilities Under Tax Receivable Agreement Noncurrent
LiabilitiesUnderTaxReceivableAgreementNoncurrent
206300000 USD
CY2021Q4 amrx Liabilities Under Tax Receivable Agreement Noncurrent
LiabilitiesUnderTaxReceivableAgreementNoncurrent
206300000 USD
CY2022Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
933577000 USD
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1191792000 USD
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1679000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1665000 USD
CY2022Q1 amrx Contract Charge Backs And Sales Volume Allowances Current
ContractChargeBacksAndSalesVolumeAllowancesCurrent
371015000 USD
CY2021Q4 amrx Contract Charge Backs And Sales Volume Allowances Current
ContractChargeBacksAndSalesVolumeAllowancesCurrent
503902000 USD
CY2022Q1 amrx Cash Discount Allowances Current
CashDiscountAllowancesCurrent
22574000 USD
CY2021Q4 amrx Cash Discount Allowances Current
CashDiscountAllowancesCurrent
23642000 USD
CY2022Q1 amrx Allowance For Accounts Receivable Current
AllowanceForAccountsReceivableCurrent
395268000 USD
CY2021Q4 amrx Allowance For Accounts Receivable Current
AllowanceForAccountsReceivableCurrent
529209000 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
538309000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
662583000 USD
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
212849000 USD
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
214508000 USD
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
64519000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
47802000 USD
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
234873000 USD
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
227079000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
512241000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
489389000 USD
CY2022Q1 us-gaap Interest Rate Cash Flow Hedge Liability At Fair Value
InterestRateCashFlowHedgeLiabilityAtFairValue
42151000 USD
CY2022Q1 amrx Deferred Compensation Plan Liabilities Fair Value Disclosures
DeferredCompensationPlanLiabilitiesFairValueDisclosures
12817000 USD
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
14896000 USD
CY2021Q4 us-gaap Interest Rate Cash Flow Hedge Liability At Fair Value
InterestRateCashFlowHedgeLiabilityAtFairValue
11473000 USD
CY2021Q4 amrx Deferred Compensation Plan Liabilities Fair Value Disclosures
DeferredCompensationPlanLiabilitiesFairValueDisclosures
13883000 USD
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
5900000 USD
CY2022Q1 us-gaap Aoci Loss Cash Flow Hedge Cumulative Gain Loss After Tax
AociLossCashFlowHedgeCumulativeGainLossAfterTax
-42200000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
593017000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
522814000 USD
CY2022Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
7553000 USD
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
70584000 USD
CY2022Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
3075000 USD
CY2021 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
0 USD
CY2022Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-752000 USD
CY2021 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-381000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
602893000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
593017000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1339174000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
534781000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
804393000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1256412000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
494915000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
761497000 USD
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
405425000 USD
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
405425000 USD
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
405425000 USD
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
405425000 USD
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
1744599000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
534781000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1209818000 USD
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
1661837000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
494915000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1166922000 USD
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
40919000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
41672000 USD
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
405400000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
126846000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
156567000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
148179000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
110773000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
64159000 USD
CY2022Q1 amrx Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
197869000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
804393000 USD
CY2022Q1 us-gaap Loss Contingency Receivable
LossContingencyReceivable
37000000 USD
CY2021Q4 us-gaap Loss Contingency Receivable
LossContingencyReceivable
33000000 USD
CY2022Q1 amrx Loss Contingency Pending Claims Including Third Parties Number
LossContingencyPendingClaimsIncludingThirdPartiesNumber
914 case
CY2022Q1 amrx Loss Contingency Number Of Cases
LossContingencyNumberOfCases
115 case
CY2022Q1 amrx Loss Contingency Number Of States With Cases
LossContingencyNumberOfStatesWithCases
11 state
CY2022Q1 amrx Loss Contingency New Lawsuit Filed Number
LossContingencyNewLawsuitFiledNumber
2 lawsuit
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 segment
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
497633000 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
323062000 USD
CY2022Q1 us-gaap Gross Profit
GrossProfit
174571000 USD
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
98665000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52798000 USD
CY2022Q1 us-gaap Royalty Expense
RoyaltyExpense
764000 USD
CY2022Q1 amrx Business Combination Acquisition Related Costs Transaction Related And Integration Expense
BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense
434000 USD
CY2022Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
2326000 USD
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
731000 USD
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
200000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
23305000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493105000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
301543000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
191562000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90726000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48182000 USD
CY2021Q1 us-gaap Royalty Expense
RoyaltyExpense
3582000 USD
CY2021Q1 amrx Business Combination Acquisition Related Costs Transaction Related And Integration Expense
BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense
2802000 USD
CY2021Q1 us-gaap Restructuring Charges
RestructuringCharges
363000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
45907000 USD
CY2022Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0 USD
CY2021Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0 USD
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
15960000 USD
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
47861000 USD
CY2022Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1175000 USD
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1179000 USD
CY2022Q1 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
10371000 USD
CY2021Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
9619000 USD
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
4400000 USD
CY2021Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
9200000 USD
CY2021 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
16717000 USD
CY2021 amrx Changes In Reallocation Of Ownership Interests
ChangesInReallocationOfOwnershipInterests
-226000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
24590000 USD
CY2022Q1 amrx Changes In Reallocation Of Ownership Interests
ChangesInReallocationOfOwnershipInterests
-112000 USD
CY2022Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1595000 USD
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1174000 USD
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
4841000 USD
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
7962000 USD
CY2022Q1 amrx Prepaid Regulatory Fees Current
PrepaidRegulatoryFeesCurrent
2539000 USD
CY2021Q4 amrx Prepaid Regulatory Fees Current
PrepaidRegulatoryFeesCurrent
3710000 USD
CY2022Q1 amrx Income And Other Taxes Receivable
IncomeAndOtherTaxesReceivable
10466000 USD
CY2021Q4 amrx Income And Other Taxes Receivable
IncomeAndOtherTaxesReceivable
8850000 USD
CY2022Q1 us-gaap Prepaid Taxes
PrepaidTaxes
18255000 USD
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
16085000 USD
CY2022Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
47213000 USD
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
42770000 USD
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
23562000 USD
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
17309000 USD
CY2022Q1 amrx Chargebacks Receivable Current
ChargebacksReceivableCurrent
12937000 USD
CY2021Q4 amrx Chargebacks Receivable Current
ChargebacksReceivableCurrent
12358000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
121408000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
110218000 USD
CY2022Q1 us-gaap Loss Contingency Receivable
LossContingencyReceivable
37000000 USD
CY2021Q4 us-gaap Loss Contingency Receivable
LossContingencyReceivable
33000000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
63943000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20614000 USD
CY2021Q4 amrx Number Of Companies
NumberOfCompanies
55 company
CY2021Q4 us-gaap Grants Receivable
GrantsReceivable
10000000000 INR
CY2021Q4 us-gaap Grants Receivable
GrantsReceivable
132300000 USD
CY2021Q4 amrx Government Grant Eligible Term
GovernmentGrantEligibleTerm
P6Y

Files In Submission

Name View Source Status
0001723128-22-000016-index-headers.html Edgar Link pending
0001723128-22-000016-index.html Edgar Link pending
0001723128-22-000016.txt Edgar Link pending
0001723128-22-000016-xbrl.zip Edgar Link pending
amrx-20220331.htm Edgar Link pending
amrx-20220331.xsd Edgar Link pending
amrx-2022033110xqexx311.htm Edgar Link pending
amrx-2022033110xqexx312.htm Edgar Link pending
amrx-2022033110xqexx313.htm Edgar Link pending
amrx-2022033110xqexx321.htm Edgar Link pending
amrx-2022033110xqexx322.htm Edgar Link pending
amrx-2022033110xqexx323.htm Edgar Link pending
amrx-20220331_cal.xml Edgar Link unprocessable
amrx-20220331_def.xml Edgar Link unprocessable
amrx-20220331_htm.xml Edgar Link completed
amrx-20220331_lab.xml Edgar Link unprocessable
amrx-20220331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending